ES2138960T3 - Tratamiento del fallo de la lactacion humana. - Google Patents

Tratamiento del fallo de la lactacion humana.

Info

Publication number
ES2138960T3
ES2138960T3 ES91916584T ES91916584T ES2138960T3 ES 2138960 T3 ES2138960 T3 ES 2138960T3 ES 91916584 T ES91916584 T ES 91916584T ES 91916584 T ES91916584 T ES 91916584T ES 2138960 T3 ES2138960 T3 ES 2138960T3
Authority
ES
Spain
Prior art keywords
treatment
failure
higf
human
human lactation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91916584T
Other languages
English (en)
Inventor
Peter Gluckman
Stella Ruth Milsom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2138960T3 publication Critical patent/ES2138960T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processing Of Solid Wastes (AREA)
  • Treatment Of Sludge (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dairy Products (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE HGH, HIGF-1, HIGF-2 O DE ANALOGOS DE ESTOS O DE UNA MEZCLA DE UNO O MAS DE ESTOS, POR SI SOLOS O JUNTO CON INTENSIFICADORES DE LA SECRECION DE LECHE PARA EL TRATAMIENTO DE LA FALTA DE SECRECION DE LECHE HUMANA. TAMBIEN SE REFIERE AL USO DE HGH, HGRF, HIGF-1, HIGF-2 O DE ANALOGOS DE ESTOS O DE UNA MEZCLA DE DOS O MAS DE ESTOS, POR SI SOLOS O JUNTO CON INTENSIFICADORES DE LA SECRECION DE LECHE PARA LA PRODUCCION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA FALTA DE SECRECION DE LECHE HUMANA, ASI COMO PARA UN TRATAMIENTO PROFILACTICO. PREFERENTEMENTE SE UTILIZA UNA HORMONA DE CRECIMIENTO HUMANA. LA INVENCION TAMBIEN SE REFIERE A UN METODO PARA EL TRATAMIENTO DE LA FALTA DE SECRECION DE LECHE HUMANA ASI COMO A LAS COMPOSICIONES Y LOS METODOS PARA SU PRODUCCION.
ES91916584T 1990-08-03 1991-07-19 Tratamiento del fallo de la lactacion humana. Expired - Lifetime ES2138960T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ23476690 1990-08-03

Publications (1)

Publication Number Publication Date
ES2138960T3 true ES2138960T3 (es) 2000-02-01

Family

ID=19923318

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91916584T Expired - Lifetime ES2138960T3 (es) 1990-08-03 1991-07-19 Tratamiento del fallo de la lactacion humana.

Country Status (13)

Country Link
US (1) US5276014A (es)
EP (1) EP0652767B1 (es)
JP (1) JP3074302B2 (es)
AT (1) ATE184489T1 (es)
AU (1) AU643073B2 (es)
CA (1) CA2086754C (es)
DE (1) DE69131629T2 (es)
DK (1) DK0652767T3 (es)
ES (1) ES2138960T3 (es)
GR (1) GR3032156T3 (es)
IE (1) IE912345A1 (es)
PT (1) PT98563B (es)
WO (1) WO1992002245A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260309A (en) * 1992-06-08 1997-07-27 Pharmacia Ab Substituted For K Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth
CN1174504A (zh) * 1993-11-09 1998-02-25 麦克公司 促进生长激素释放的哌啶、吡咯烷和六氢－1h－吖庚因
WO1996009065A1 (en) * 1994-09-21 1996-03-28 Pharmacia & Upjohn Ab Method of treating hypertension in pregnant mammals
AU4318496A (en) * 1994-12-21 1996-07-10 Auckland Uniservices Limited Enhancement of fetal growth by administration of insulin-likegrowth factor-1(IGF-1)
GR1007178B (el) * 1995-02-22 2011-01-31 Πετρομανωλακης Εμμ. Πρωραιος αγωγος σκαφους με διατομην αεροτομης.
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853833A (en) * 1971-04-27 1974-12-10 Hormone Res Foundation Synthetic human growth-promoting and lactogenic hormones and method of producing same
BG49718A3 (bg) * 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
ES2001203A6 (es) * 1985-08-12 1988-05-01 Syntex Inc Procedimiento para preparar el polipeptido factor liberador de la hormona del crecimiento bovina
US4783524A (en) * 1985-09-17 1988-11-08 Monsanto Company Growth factors
CA1299103C (en) * 1986-03-07 1992-04-21 Robert Joseph Collier Method and compositions for increasing mammary parenchyma
IL86102A (en) * 1987-05-11 1994-04-12 Univ Tulane Alkylated growth hormone-releasing peptides and use thereof
FR2622455B1 (fr) * 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5089473A (en) * 1988-08-29 1992-02-18 Monsanto Company Somatotropin variants and their use

Also Published As

Publication number Publication date
JP3074302B2 (ja) 2000-08-07
DE69131629D1 (de) 1999-10-21
PT98563A (pt) 1992-06-30
US5276014A (en) 1994-01-04
EP0652767A1 (en) 1995-05-17
GR3032156T3 (en) 2000-04-27
CA2086754A1 (en) 1992-02-04
ATE184489T1 (de) 1999-10-15
JPH05509329A (ja) 1993-12-22
CA2086754C (en) 2000-08-29
AU643073B2 (en) 1993-11-04
PT98563B (pt) 1999-01-29
DK0652767T3 (da) 2000-04-03
WO1992002245A1 (en) 1992-02-20
AU8510891A (en) 1992-03-02
EP0652767B1 (en) 1999-09-15
IE912345A1 (en) 1992-02-12
DE69131629T2 (de) 2000-03-09

Similar Documents

Publication Publication Date Title
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
SE8802569D0 (sv) Improvements in or relation to somatostatins
MX169205B (es) Composicion para estimular el crecimiento del cabello
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
EP1201241A3 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
EP0489108A4 (en) Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
ES2102393T3 (es) Complejos de acido quinolona carboxilico--ion metalico--acido.
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
MX9701187A (es) Nuevas lactamas naftofusionadas n-substituidas.
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
GR3032156T3 (en) Treatment of human lactation failure.
HU901095D0 (en) Process for producing compound reducing extraction of gastric acid and pharmaceutical preparative containing said compound
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.
ZA935046B (en) Use of lysozyme dimer and compositions containing the same
EP0315118A3 (en) Dna coding for endothelin and use thereof
AU567018B2 (en) Prazosin-pirbuterol combination for bronchoduation
Beitner et al. Prostaglandin E1 treatment of leg ulcers caused by venous or arterial incompetence
ATE93730T1 (de) Methode zur erhoehung des wachstums des brustzellgewebes.
EP0093497A3 (en) Anthelmintic treatment
GB1507643A (en) 4-(5-nitro-2-furyl)quinaldinic acid n-oxide and its use in the treatment of bovine mastitis
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
ATE28384T1 (de) Medizinisches verfahren und zubereitung.
RU2014020C1 (ru) Способ лечения стилоидита
IT1209298B (it) Composizione farmaceutica per la somministrazione topica di nifedipina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652767

Country of ref document: ES